1. Introduction
The machinery regulating the transcription and processing of the human immunodeficiency virus type 1 (HIV-1) genome has been extensively studied for the past two decades, leading to the characterization of a complex set of interactions between viral and cellular factors. Our understanding of the basic molecular mechanisms regulating the expression of cellular genes has been greatly advanced by the lessons learned from this virus. Studies aimed at the understanding of transcription, capping, polyadenylation, splicing and export of the viral transcripts have helped in modeling the mechanisms regulating transcriptional and post-transcriptional events in the cell. Recent developments in the field have also shown that, similarly to cellular genes, transcription and processing of the viral mRNAs are functionally coupled and can potentially be regulated by small non-coding RNAs.
HIV replication is a complex multistep process whereby, following the recognition of specific receptors and co-receptors on the host cell membrane, the virus enters the cell where the viral RNA genome is reverse transcribed and integrated into the cellular DNA. The integrated proviral genome is than transcribed by the host transcription machinery into a 9.2 kb primary transcript, which is alternatively spliced in mRNAs coding for the 9 viral genes.
HIV-1 has developed a number of strategies to regulate the transcription and processing of its primary transcript. Interactions between viral RNA sequences, the host cell and viral proteins are necessary to express the nine gene products required for its replication. Alteration of the delicate balance between spliced and unspliced RNAs, or disruption of the viral RNA export pathway, can dramatically affect HIV-1 infectivity and pathogenesis (Amendt, et al., 1994, Jablonski & Caputi, 2009, Pollard & Malim, 1998, Purcell & Martin, 1993, Stoltzfus & Madsen, 2006, Wentz, et al., 1997). A better understanding of the mechanisms regulating the transcription and processing of the viral RNA may provide us with novel therapeutic targets.
2. HIV-1 transcription regulation
Once the virus is integrated into the host cell chromosome the viral genome is transcribed into a single pre-mRNA from a complex promoter located within the 5’ long terminal repeat (LTR) of the viral genome. The HIV-1 LTR promoter contains two Sp1 binding motifs and two nuclear factor NF-kB binding sites which serves to regulate basal HIV-1 transcription (Pereira, et al., 2000). The LTR also contains binding elements for positive nuclear factor of activated T cells, AP-1, and negative, YY1 and LSF, transcriptional regulators. Tumor necrosis factor-α (TNF-α) and other cytokines can induce NF-kb and activate HIV-1 transcription in infected cells (Van Lint, et al., 2004). Transcription regulation of the HIV-1 genome is mediated by RNA polymerase II (RNAP II) and a combination of basal and promoter specific factors (Fig. 2) (Brady & Kashanchi, 2005, Pereira, et al., 2000).
Shortly after transcription begins RNAP II activity is paused. Before transcription is halted a short (nucleotides +1 to +82) stem loop sequence, the transactivation responsive (TAR) RNA, is synthesized. Binding of the 101 amino acid viral regulatory protein Tat to TAR stimulates transcription elongation and possibly initiation of the viral transcription complex (Fig. 2) (Berkhout, et al., 1989, Gaynor, 1995, Raha, et al., 2005). The Tat-TAR interaction promote the recruitment of the cyclin T1 (CycT1) component of the human positive transcription elongation factor b (P-TEFb) (Garber, et al., 1998, Wei, et al., 1998). CycT1 recruits Cdk9, the catalytic subunit of P-TEFb, which phosphorylates the C-terminal domain (CTD) of RNAP II to facilitate elongation of the viral transcript (Bres, et al., 2008, Peterlin & Price, 2006). The mammalian RNAPII CTD is composed of 52 tandemly repeated heptads with a consensus, Tyr-1-Ser-2-Pro-3-Thr-4-Ser-5-Pro-6-Ser-7. Ser-2 and Ser-5 are targets of phosphorylation and dephosphorylation during transcription (Hirose & Ohkuma, 2007). Phosphorylation of RNAPII CTD is essential for transcription. RNAPII CTD is phosphorylated at Ser-5 by TFIIH (CDK7) during transcription initiation through the promoter clearance stage (Hengartner, et al., 1998) and changes to Ser-2 phosphorylation during elongation when the polymerase is associated with the coding region (Komarnitsky, et al., 2000, Ni, et al., 2004). In addition to promoting Ser-2 phosphorylation, Tat modifies the activity of CDK9 to phosphorylate Ser-5 following release of TFIIH (Zhou, et al., 2000). Furthermore, P-TEFb targets cofactors such as the human homologoue of SPT5 (TAT-CT1), which together with SPT4 constitutes the 5,6-dichloro-1-ß-D-ribofuranosylbenzimidazole sensitivity-inducing factor (DSIF) and the negative elongation factor (NELF) Rd protein (Yamaguchi, et al., 1999). The cooperative interaction of DSIF and NELF induce polymerase pausing near promoter start sites (Wada, et al., 2000, Wada, et al., 1998b). This pausing event can be reversed by a CDK9-dependent phosphorylation of SPT5 (Kim & Sharp, 2001) and the RD protein, which causes a dissociation of NELF from the stem of TAR RNA (Fujinaga, et al., 2004).
Tat role in viral transcription is not limited to the recruitment of RNAP II cofactors. Once integrated into the host cell genome, nucleosomes are deposited at specific positions within the viral promoter and exert a strong repression of transcriptional initiation. After Tat activates transcription, the chromatin associated with sequences immediately downstream of the transcription start site becomes accessible to nucleases (Verdin, et al., 1993). The chromatin remodeling induced by Tat is dependent on the recruitment of enzymes with histone acetyl transferase (HAT) activity, which modify chromatin conformation (Marcello, et al., 2001). These factors include the transcriptional co-activators p300 and the cAMP-responsive binding protein (CREB)-binding protein (CBP) (Marzio, et al., 1998), the p300/CBP-associated factor (P/CAF) (Benkirane, et al., 1998), the general control non-derepressible-5 (GCN5) factor (Col, et al., 2001), the transcription factor TAFII250 (Weissman, et al., 1998) and the TIP60 protein (Kamine, et al., 1996). HATs acetylate the N-terminal tails of histones to stimulate chromatin remodeling and modify specific lysines of transcription factors to modulate DNA-binding affinity (Li, et al., 2007, Yang & Seto, 2008). In addition to histones, Tat itself is a substrate for acetylation by HATs. Lysines at positions 50 and 51 are major substrates for acetylation by p300 and hGCN5 (Col, et al., 2001, Deng, et al., 2001, Kiernan, et al., 1999). Acetylation of lysine 50 of Tat promotes the dissociation of Tat from TAR RNA during early transcription elongation and recruitment of the SWI/SNF chromatin-remodeling complex (Treand, et al., 2006), which synergize with p300 acetyltransferase and acetylated Tat to remodel the nucleosome at the HIV promoter in order to activate transcription (Mahmoudi, et al., 2006). Furthermore, acetylation of lysine 50 triggers the recruitment of P/CAF to the elongating RNA Pol II (Dorr, et al., 2002). P/CAF acetylates Tat on Lys28 (Kiernan, et al., 1999), which enhances the Tat-CycT1 interaction (Bres, et al., 2002). Besides acetylation other post-translational modifications appear to regulate Tat activity. Phosphorylation of Tat Ser16 and Ser46 by the cell cycle regulator Cdk2/cyclin E appears to be required for efficient HIV-1 transcription and replication (Ammosova, et al., 2006). Methylation of Tat on arginine residues by PRMT6 has been shown to inhibit transcriptional activity (Boulanger, et al., 2005), while non-proteolytic ubiquitination of Tat by Hdm2 appears to enhance viral transcription (Bres, et al., 2003).
In addition to its role in viral transactivation, Tat has also been shown to regulate the rate of transcription and expression of host cellular genes (Caldwell, et al., 2000, Gibellini, et al., 2002, Huang, et al., 1998, Ott, et al., 1998, Secchiero, et al., 1999). Furthermore, Tat function appears not to be restricted to infected cells, which actively secrete large amounts of Tat in the bloodstream (Ensoli, et al., 1990). Extracellular Tat can generate a wide array of cell responses ranging from T-cell activation (Wu, et al., 2007) to stimulation of cytokine secretion, cell death in neurons and cell proliferation in endothelial and T-cells (Huigen, et al., 2004, King, et al., 2006, Rubartelli, et al., 1998). The mechanism by which Tat exerts these pleiotropic effects is still unclear.
3. HIV-1 mRNA processing
Before a gene transcript is ready to be transported out of the nucleus it has to be processed by acquiring a cap structure at the 5’ terminus, introns have to be spliced out and a 3’ end is generated by adding a poly(A) tail. Although these reactions are biochemically distinct processes, they are interlinked and influence one another’s specificity and efficiency. Most mechanisms regulating the processing of viral transcripts are common to most cellular mRNAs, nevertheless some processes, such as the export of the unspliced and partially spliced mRNAs to the cytoplasm, are unique for the virus.
3.1. Capping
mRNA capping is carried out by a series of enzymatic reactions in which the 5’ triphosphate terminus of the pre-mRNA is cleaved to a diphosphate by a RNA triphosphatase (RTP), then capped with GMP by RNA guanylyltransferase (GT), and methylated by RNA (guanine-N7) methyltransferase (MT). Targeting of Cap formation to transcripts made by RNAP II is achieved through the interaction of the capping enzymes with the phosphorylated RNAPII CTD. The Cap structure is recognized by the Cap binding complex (CBC), which contains the proteins, CBP20 and CBP80 (Proudfoot, et al., 2002, Shatkin & Manley, 2000). HIV-1 capping takes place during the transition from transcription initiation to elongation when the nascent pre-mRNA is only 20–40 nucleotides long. Tat promotes viral mRNA Cap formation by inducing TAR-dependent phosphorylation of RNAPII CTD (Chiu, et al., 2002, Zhou, et al., 2003) Phosphorylation of the CTD Ser-2 and Ser-5 residues has differential effects on recruitment and activation of capping enzymes (Bentley, 2002, Proudfoot, et al., 2002). Although Ser-2 phosphorylation of CTD heptads is sufficient for mammalian GT binding, its activation requires Ser-5 phosphorylated CTD (Ho & Shuman, 1999).
3.2. 3’ end formation
In higher eukaryotes, with the exception of histone genes, all protein encoding mRNAs contain a uniform 3’ end consisting of 200-400 adenosine residues. The poly(A) tail regulates degradation of the mRNA and translation. The formation of the poly (A) tail is directed by sequences present on the pre-mRNA and the mammalian polyadenylation machinery. Prior to the addition of poly(A), the pre-mRNA must be cleaved. The site of cleavage, in most pre-mRNAs, lies between a highly conserved AAUAAA hexamer and a downstream sequence element (DSE), which is a U- or GU-rich motif. The cleavage/ poly(A) complex consists of cleavage factors (CPSF, CstF, CF) and the poly(A) polymerase (PAP). RNA is first cleaved ~10 to 30 nts 3' to AAUAAA, predominantly at a CA dinucleotide, than the PAP synthesizes a polyA tail using ATP as substrate (Proudfoot, et al., 2002, Shatkin & Manley, 2000).
HIV-1 encodes the polyadenylation signal within the repeat (R) region, which is present at the extreme 5' and 3' end of the viral transcript. Thus the 5' polyadenylation signal needs to be repressed while usage of the 3’ one needs to be enhanced. Usage of the 3' polyadenylation site is promoted by an upstream enhancer (USE) motif, which stabilizes binding of the cleavage polyadenylation specificity factor (CPSF) to the AAUAAA (Gilmartin, et al., 1995). The 5' HIV-1 polyadenylation site is repressed because it is positioned too close to the transcription initiation site and polyadenylation factors have not yet gained access to the nascent transcript through the RNAP II complex (Cherrington & Ganem, 1992, Weichs an der Glon, et al., 1991). Moreover, binding of U1 snRNP to the major splice donor site, which is located downstream of 5' R, represses polyadenylation at the 5' polyadenylation signal (Ashe, et al., 1995, Ashe, et al., 1997). Cellular proteins can play a role in regulating cleavage and polyadenylation of HIV-1 RNA. hnRNP U has been shown to be involved in the post-transcriptional regulation of viral RNA via interactions with the 3’ UTR (Valente & Goff, 2006). The STAR (signal transduction and activation of RNA) protein family member Sam68 enhances HIV-1 gene expression and this effect may be due in part to Sam68’s ability to stimulate cleavage of unspliced viral RNA (Mc Laren, et al., 2004, Reddy, et al., 1999). Experimental evidence also indicates a role for viral proteins in regulating the host polyadenylation machinery to render the cell more supportive of virus replication. The accessory protein Vpr induces polyA polymerase dephosphorylation and its subsequent activation (Mouland, et al., 2002), while Tat increases the expression of the cleavage and polyadenylation specificity factor (CPSF) (Calzado, et al., 2004).
3.3. mRNA Splicing
The removal of intronic sequences in the nascent transcript is carried out by large multicomponent ribonucleoprotein complex, the spliceosome, constituted by five small nuclear ribonucleoprotein complexes (snRNPs, U1, U2, U4, U5, U6), which assembly onto the pre-mRNA requires auxiliary proteins called splicing factors (Moore, et al., 1993). The process of splicing involves recognition of short loosely conserved sequences flanking the introns. The U1 snRNP recognizes the 5’ splice site (5’ss) while the U2 snRNP in combination with the splicing factor U2AF65/35 recognizes sequences at the 3’ splice site (3’ss). 5' and 3' splice sites are required for splicing but alone are not sufficient for the proper recognition of exonic and intronic sequences.
Additional regulatory elements are classified as either exonic and intronic splicing enhancers (ESE and ISE) or exonic and intronic splicing silencers (ISS and ESS). These sequences can interact with factors that promote proper recognition of the splice sites and regulate splicing in response to physiological stimuli. Among the best-characterized ESEs are purine-rich sequences that recruit members of the serine/arginine-rich (SR) family of splicing activators (Blencowe, 2000). SR proteins regulate splicing by binding enhancer elements and recruiting and stabilizing components of the core splicing machinery to nearby splice sites (Graveley, 2000). Recent work implicates SR proteins in additional steps of gene expression, including mRNA export, stability, quality control and translation (Huang & Steitz, 2005). The best-known ESSs are dependent on interactions with members of the heterogenous ribonucleoprotein A/B family (hnRNPs A/B) (Krecic & Swanson, 1999). Positive and negative
Alternative splicing is a process common to most cellular mRNAs by which exons from a primary transcript (pre-mRNA) can be spliced in different arrangements to yield mRNAs that will produce functionally different protein variants (Black, 2003). The primary viral transcript undergoes a complex series of splicing events to generate over 40 mRNA isoforms, thus, the same viral protein is encoded by multiple mRNAs that vary for their 5’ and 3’ untranslated regions. Spliced viral mRNAs can be classified in a group of approximately 4kb in length, coding for the Env, Vpu, Vpr and Vif proteins, and a group of approximately 2 kb in length, coding for the Tat, Rev, Vpr and Nef proteins (Fig. 3C) (Purcell & Martin, 1993). Furthermore, approximately 50% of the viral pre-mRNAs leave the nucleus without being spliced. The unspliced 9 kb mRNA codes for the Gag and Gag-Pol polyprotein and is packaged within the nascent virions as viral genome. Alteration of this complex splicing pattern can have profound effects on viral replication and infectivity (Amendt, et al., 1994, Jablonski, et al., 2008, Jacquenet, et al., 2005, Purcell & Martin, 1993). HIV-1 splicing regulation relies on the presence of multiple viral regulatory sequences as well as cellular splicing factors that interact with these elements. To date, 4 exonic splicing silencers (ESS), 1 intronic splicing silencer (ISS), 1 intronic splicing enhancer (ISE) and 6 splicing exonic enhancers (ESE) have been identified (Fig. 3B) (Exline, et al., 2008, McLaren, et al., 2008, Schaub, et al., 2007). Several SR proteins (SC35, SF2, SRp40, 9G8) have been shown to bind the viral splicing enhancers and regulate splicing, while members of the hnRNP A/B (A1, A2 and A3) family have been shown to inhibit the usage of viral splice sites by binding viral spicing silencer elements and counteracting the activity of SR proteins (McLaren, et al., 2008). A third group of proteins interacts with both, enhancer and silencer sequences, is the hnRNP H family (H’, F, 2H9 and GRSF1). These are highly homologous and ubiquitously expressed factors, which regulate splicing, polyadenylation, capping, export and translation of cellular and viral mRNAs (Fogel & McNally, 2000, Han, et al., 2005, Jablonski & Caputi, 2009, Min, et al., 1995, Schaub, et al., 2007).
Cis-acting splicing regulatory elements within the HIV genome are highly heterogenous, redundant and provide for ample regulation of viral genome expression. In addition, the virus appears to directly regulate the relative amount and activity of cellular splicing factors in infected cells. HIV-1 infection has been shown to induce alteration in SR protein subcellular distribution, and activity via modificaton of their phosphorylation state by SR-specific kinases (Fukuhara, et al., 2006). Furthermore, data obtained from infected monocyte-derived macrophages demonstrate that a peak in viral production results in down-regulation of members of the hnRNP A/B, H and SR family, thus confirming the critical role that these proteins may play in viral replication. (Dowling, et al., 2008).
3.4. mRNA export and stability
In the early phase of viral infection the 2 kb class of viral RNAs (translated into Tat, Rev and Nef) is exported to the cytoplasm while 9 and 4 kb viral RNAs are retained in the nucleus. Nuclear retention of 9 and 4 kb HIV-1 RNAs has been attributed to either partial spliceosome assembly (Chang & Sharp, 1989) or to a series of of poorly characterized sequences called the instability (INS) or
Nuclear retention of the unspliced and partially spliced viral mRNAs (9 and 4 kb) is overcome by the viral protein Rev, which is imported into the nucleus and binds to an RNA element within the
Little is known of cellular co-factors required by Rev-RRE other than the general nuclear export factors exportin CRM1 and RAN-GTP. RNA helicases DDX1 and DDX3 are known to associate with the Rev-CRM1-RRE complex and are postulated to aid the egress of the viral RNA through the nuclear pore by remodeling its structure (Fang, et al., 2004, Yedavalli, et al., 2004). Other factors such as the eukaryotic initiation factor eIF-5A (Bevec, et al., 1996, Ruhl, et al., 1993), the human Rev interacting protein (hRIP) (Bogerd, et al., 1995, Fritz, et al., 1995) and Sam68 (Reddy, et al., 1999) have also been shown to enhance Rev activity although their mechanism is still unclear. Cellular factors may also play an inhibitory role in Rev-dependent RNA export. The C-terminal variant of nuclear factor 90 (NF90ctv) has been shown to reduce Rev function by binding and partially relocalizing Rev to the cytoplasm (Urcuqui-Inchima, et al., 2006), while Rev methylation by the arginine methylase PRMT6 reduces Rev binding to the RRE and blocks viral RNA export (Invernizzi, et al., 2006).
4. Transcription and mRNA processing coupling
In recent years our view of gene expression has changed significantly. While a growing number of genetic studies have revealed functional links between the factors that carry out the different steps in the gene expression pathway, conventional biochemical approaches and large-scale mapping of protein-protein interaction networks have uncovered physical interactions between the various machineries (Orphanides & Reinberg, 2002, Proudfoot, et al., 2002). The transcriptional apparatus plays an active role in recruiting the machinery that processes the nascent RNA transcript (Bentley, 2002, Bentley, 2005). The RNAPII CTD operates as a binding platform for components of the RNA processing machineries and its phosphorylation regulates the activity of the capping enzymes, assembly of the spliceosome and the binding of the cleavage/polyadenylation complex (Buratowski, 2003, Fong & Bentley, 2001, Hirose & Ohkuma, 2007, Komarnitsky, et al., 2000, Proudfoot, et al., 2002).
The mechanism coupling 5’ RNA capping with transcription has been well studied. Binding of the DSIF factor (Wada, et al., 1998a, Wada, et al., 1998b) to RNAPII shortly after initiation recruits NELF (Yamaguchi, et al., 1999), which arrests transcription. The cdk7 subunit of the initiation factor TFIIH phosphorylates the RNAPII CTD Ser-5 between initiation and arrest (Woychik & Hampsey, 2002). The paused RNAP II is then joined by the capping enzymes through interactions with the Ser-5 phosphorylated CTD and DSIF (Wada, et al., 1998b, Wen & Shatkin, 1999). Following the addition of the Cap, the kinase activity of P-TEFb phosphorylates DSIF (Ivanov, et al., 2000, Kim & Sharp, 2001), this neutralizes the repressive action of NELF and allows the polymerase to resume elongation. Similary 3' End formation is also linked to transcription. The cleavage/polyadenylation factors CPSF and CstF are transferred by the RNAP II CTD to their specific pre-mRNA-binding sites to produce the mRNA 3' end (Buratowski, 2005). Splicing and 3’ end formation machineries are also connected since repression of the polyadenylation signal within the R5 region is dependent on proximity to the promoter and recognition of the major 5’ splice site by the U1 snRNP (Ashe, et al., 1995, Ashe, et al., 1997).
Several studies have also shown that transcription and splicing are closely connected processes. The rate of elongation, the promoter type, transcriptional activators and the chromatin remodeling factors nearby can all affect splicing of a pre-mRNA (Batsche, et al., 2006, de la Mata, et al., 2003, Kornblihtt, 2005, Kornblihtt, 2007). Again, the RNAPII CTD assumes a central role in the regulation of RNA splicing. Phosphorylation at Ser-2 position of the RNAPII CTD stimulates pre-mRNA splicing (Hirose, et al., 1999, Misteli & Spector, 1999). Studies have identified several splicing factors that interact either directly or indirectly with the transcription machinery (Kameoka, et al., 2004, Kwek, et al., 2002). Many of the works published indicate processes that link the transcription machinery to pre-mRNA splicing. However, a “reverse coupling” mechanism, whereby pre-mRNA splicing exerts an influence on transcription has also been described. Indeed, the SR protein SC35 has been shown to affect transcription elongation (Lin, et al., 2008) and promoter-proximal 5´ splice sites increase transcription initiation via recruitment of the transcription preinitiation complex (PIC) (Damgaard, et al., 2008).
Studies on the association between the viral transcription and splicing machinery are still in their infancy. Research indicates that the cellular factor Tat-SF1, which is required for efficient transcriptional transactivation of the viral genome (Parada & Roeder, 1999, Zhou & Sharp, 1996), is also interacting with spliceosomal components (Fong & Zhou, 2001). The association with both elongation and splicing factors has led to the suggestion that Tat-SF1 can couple these two processes. Tat-SF1 also binds to another transcription-splicing coupling factor, CA150 (TCERG1) (Smith, et al., 2004). Over-expression of CA150 has been shown to reduce the ability of Tat to mediate viral transcription (Sune & Garcia-Blanco, 1999). This function is dependent on the association of CA150 with pre-mRNA splicing factors and RNAPII CTD (Carty, et al., 2000, Goldstrohm, et al., 2001) and may bridge splicing complexes to actively transcribing RNAPII (Sanchez-Alvarez, et al., 2006). The cellular protein c-Ski-interacting protein, SKIP, has been shown to regulate Tat-dependent viral transcription and interact with the splicing associated U5 snRNP and the tri-snRNP 110K protein (Bres, et al., 2005). Studies also indicate the presence of a reverse coupling mechanism in HIV-1. U1 snRNA binding to a specific 5’ splice site within the viral genome appears to overcome a checkpoint for elongation present in the
The viral transactivator Tat has also been shown to regulate viral splicing through the ASF/SF2 inhibitor p32 (Berro, et al., 2006). p32 is recruited to the HIV-1 promoter by the acetylated form of Tat, suggesting a mechanism by which acetylation of Tat promotes binding of p32 and thereby inhibits HIV-1 splicing, thus increasing the amounts of unspliced transcripts available for being translated into
5. HIV-1 derived microRNAs
MicroRNAs (miRNAs) are short non-coding RNA molecules encoded by most eukaryotic life forms ranging from plants to higher order mammals. miRNAs have multiple pre- and post-transcriptional roles in the regulation of gene expression. The first step in the biogenesis of miRNA is the nuclear processing of primary RNA transcripts (pri-miRNAs) approximately 80 nucleotide long into shorter (~60nt) pre-miRNAs, which are exported to the cytoplasm where pre-miRNA are further processed into mature miRNAs and assembled into a ribonucleoprotein complex named RISC (RNA-induced silencing complex) (Chua, et al., 2009, Perron & Provost, 2008, Winter, et al., 2009). The RISC complex and the associated miRNA often contain sequences complementary to the 3’ UTR region of the target mRNAs. Perfect complementarity between the target sequence and the miRNA triggers degradation of the target RNA. However, when miRNA and target mRNA sequences are only partially complementary the mRNA is translationaly repressed. Furthermore, miRNA can also operate at chromatine level. miRNAs have been shown to associate with the RNA-induced initiation of transcriptional silencing (RITS) complex and be recruited to complementary sequences in the chromosomal DNA. This promotes the activity of histone modifying enzymes, which alter the chromatin structure and induce transcriptional silencing (Buhler & Moazed, 2007, Verdel, et al., 2004).
Several HIV-1 encoded non-coding RNAs have been identified. In particular, the stem-loop TAR sequence is structurally similar to a pre-miRNA and it has been shown to be processed into two functional miRNAs, the 5’ stem (miR-TAR-5p) and the 3’ stem (miR-TAR-3p) (Klase, et al., 2007, Klase, et al., 2009, Ouellet, et al., 2008). miR-TAR-3p acts as an inhibitor of cellular gene expression targeting genes regulating stress induced cell death (Klase, et al., 2009). The downregulation of the host machinery by viral miRNAs is part of the viral strategies to prolong the life span of an infected cell and allows for efficient viral replication and the emergence of latently infected cells. Additionally, it has been shown that the TAR-derived miRNA can downregulate gene expression by recruiting chromatin remodeling components, thus inducing transcriptional silencing via the RITS mechanism (Purzycka & Adamiak, 2008).
A second miRNA is coded within the viral gene
A third miRNA generated by HIV-1, named miR-H1, is an 81 nucleotide stem loop structure present downstream of the two NF-kB sites in the LTR (Bennasser, et al., 2004). MiR-H1 has been shown to degrade the apoptosis antagonizing transcription factor (AATF) (Kaul, et al., 2009), which leads to lowered cell viability, thus counteracting the anti-apoptotic effect of the TAR-derived miRNAs. Furthermore, miR-H1 down regulates expression of the cellular miRNA miR149, which targets the Vpr gene encoded by HIV-1 (Kaul, et al., 2009). Studies on HIV-1 miRNA variability in different viral isolates have also shown that there is a strong correlation between specific miR-H1 sequences and the development of HIV-1-associated dementia and AIDS related lymphoma (Lamers, et al., 2009).
In addition to generating several viral miRNAs, HIV also regulates the cellular machinery that process small non-coding RNAs. The viral protein Tat appears to act as a generic suppressor of the activity of Dicer (Bennasser, et al., 2005), a key enzyme required for the maturation of small non-coding RNAs. Furthermore, the viral proteins Vpr and Nef have been shown to suppress the cellular miRNA machinery by suppressing production of Dicer (Coley, et al., 2011). Vertebrates have developed RNAi-based antiviral mechanisms. Given the presence in the HIV-1 genome of multiple regions that produce interfering RNAs, the anti-RNA silencing function of several viral proteins appears to be required to sustain viral replication in infected cells.
6. Future prospective
Different aspects of viral replication have been the targets of therapeutics; nevertheless, few efforts have been aimed at the disruption of the mechanism regulating viral RNA biogenesis. Formation of the HIV-1 transcript provides an important model for human RNA processing pathways and can be crucial in the isolation of novel therapeutic targets to block viral replication. Cellular factors regulating HIV RNA are expressed in most cell types and regulate a multitude of cellular splicing events theoretically making them less ideal therapeutic target candidates. Nevertheless, several drugs inhibiting different aspects of Tat transactivation are currently being tested. Different classes of compounds have been shown to specifically inhibit viral transcription by: (i) binding the TAR sequence, (ii) binding Tat, (iii) inhibiting PTEF-b components and (iv) generally inhibiting transactivation by mechanisms not yet well defined (Giacca, 2004). Small molecules that inhibit the splicing activity of SR proteins have also been shown to efficiently repress viral replication in peripheral blood mononuclear cells (PBMC) with little cell toxicity (Bakkour, et al., 2007). Furthermore, the possibility of utilizing delivery systems that specifically target cells infected by the virus (Neff, et al., 2011, Peretti, et al., 2006) suggest that cellular factors regulating the making of the viral RNA can be efficiently targeted to inhibit viral replication.
Acknowledgments
I thank Edwin Meagher for advice on the manuscript and Michelle Caputi for help in preparing it. My own work has been supported by the National Institute of Allergy and Infectious Diseases / National Institutes of Health.
References
- 1.
Alexander M. R. Wheatley A. K. Center R. J. Purcell D. F. 2010 Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor.38 3041 53 - 2.
Amelio A. L. Caputi M. Conkright M. D. 2009 Bipartite functions of the CREB co-activators selectively direct alternative splicing or transcriptional activation.28 2733 47 - 3.
Amendt B. A. Hesslein D. Chang L. J. Stoltzfus C. M. 1994 Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1.14 3960 3970 - 4.
Ammosova T. Berro R. Jerebtsova M. Jackson A. Charles S. Klase Z. Southerland W. Gordeuk V. R. Kashanchi F. Nekhai S. 2006 Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. 3,78 EOF 9 EOF - 5.
Ashe M. P. Griffin P. James W. Proudfoot N. J. 1995 Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site.9 3008 25 - 6.
Ashe M. P. Pearson L. H. Proudfoot N. J. 1997 The HIV-1 5’ LTR poly(A) site is inactivated by U1 snRNP interaction with the downstream major splice donor site.16 5752 63 - 7.
Bakkour N. Lin Y. L. Maire S. Ayadi L. Mahuteau-Betzer F. Nguyen C. H. Mettling C. Portales P. Grierson D. Chabot B. Jeanteur P. Branlant C. Corbeau P. Tazi J. 2007 Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance.3 1530 9 - 8.
Batsche E. Yaniv M. Muchardt C. 2006 The human SWI/SNF subunit Brm is a regulator of alternative splicing.13 22 9 - 9.
Benkirane M. Chun R. F. Xiao H. Ogryzko V. V. Howard B. H. Nakatani Y. Jeang K. T. 1998 Activation of integrated provirus requires histone acetyltransferase.300 and P/CAF are coactivators for HIV-1 Tat. 273, 24898-905 - 10.
Bennasser Y. Le S. Y. Benkirane M. Jeang K. T. 2005 Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.22 607 19 - 11.
Bennasser Y. Le S. Y. Yeung M. L. Jeang K. T. 2004 HIV-1 encoded candidate micro-RNAs and their cellular targets. 1,43 EOF Retrovirology EOF - 12.
Bentley D. 2002 The mRNA assembly line: transcription and processing machines in the same factory.14 336 42 - 13.
Bentley D. L. 2005 Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors.17 251 6 - 14.
Berkhout B. Silverman R. H. Jeang K. T. 1989 Tat trans-activates the human immunodeficiency virus through a nascent RNA target.59 273 82 - 15.
Berro R. Kehn K. de la Fuente C. Pumfery A. Adair R. Wade J. Colberg-Poley A. M. Hiscott J. Kashanchi F. 2006 Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator32 80, 3189-204 - 16.
Bevec D. Jaksche H. Oft M. Wohl T. Himmelspach M. Pacher A. Schebesta M. Koettnitz K. Dobrovnik M. Csonga R. Lottspeich F. Hauber J. 1996 Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A.271 1858 60 - 17.
Black D. L. 2003 Mechanisms of alternative pre-messenger RNA splicing.72 291 336 - 18.
Blencowe B. J. 2000 Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases.25 106 10 - 19.
Bogerd H. P. Fridell R. A. Madore S. Cullen B. R. 1995 Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins.82 485 94 - 20.
Boris-Lawrie K. Roberts T. M. Hull S. 2001 Retroviral RNA elements integrate components of post-transcriptional gene expression.69 2697 709 - 21.
Boulanger M. C. Liang C. Russell R. S. Lin R. Bedford M. T. Wainberg M. A. Richard S. 2005 Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression.79 124 31 - 22.
Brady J. Kashanchi F. 2005 Tat gets the "green" light on transcription initiation. 2, 69 - 23.
Bres V. Gomes N. Pickle L. Jones K. A. 2005 A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat.19 1211 26 - 24.
Bres V. Kiernan R. Emiliani S. Benkirane M. 2002 Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication.277 22215 21 - 25.
Bres V. Kiernan R. E. Linares L. K. Chable-Bessia C. Plechakova O. Treand C. Emiliani S. Peloponese J. M. Jeang K. T. Coux O. Scheffner M. Benkirane M. 2003 A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.5 754 61 - 26.
Bres V. Yoh S. M. Jones K. A. 2008 The multi-tasking P-TEFb complex.20 334 40 - 27.
Buhler M. Moazed D. 2007 Transcription and RNAi in heterochromatic gene silencing.14 1041 1048 - 28.
Buratowski S. 2003 The CTD code.10 679 80 - 29.
Buratowski S. 2005 Connections between mRNA 3’ end processing and transcription termination.17 257 61 - 30.
Caceres J. F. Stamm S. Helfman D. M. Krainer A. R. 1994 Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.265 1706 1709 - 31.
Caldwell R. L. Egan B. S. Shepherd V. L. 2000 HIV-1 Tat represses transcription from the mannose receptor promoter.165 7035 41 - 32.
Calzado M. A. Sancho R. Munoz E. 2004 Human immunodeficiency virus type 1 Tat increases the expression of cleavage and polyadenylation specificity factor 73-kilodalton subunit modulating cellular and viral expression.78 6846 54 - 33.
Carty S. M. Goldstrohm A. C. Sune C. Garcia-Blanco M. A. Greenleaf A. L. 2000 Protein-interaction modules that organize nuclear function: FF domains of CA150 bind the phosphoCTD of RNA polymerase II.97 9015 20 - 34.
Chang D. D. Sharp P. A. 1989 Regulation by HIV rev depends upon recognition of splice sites.59 789 795 - 35.
Cherrington J. Ganem D. 1992 Regulation of polyadenylation in human immunodeficiency virus (HIV): contributions of promoter proximity and upstream sequences.11 1513 24 - 36.
Chiu Y. L. Ho C. K. Saha N. Schwer B. Shuman S. Rana T. M. 2002 Tat stimulates cotranscriptional capping of HIV mRNA.10 585 97 - 37.
Chua J. H. Armugam A. Jeyaseelan K. 2009 MicroRNAs: biogenesis, function and applications.11 189 99 - 38.
Col E. Caron C. Seigneurin-Berny D. Gracia J. Favier A. Khochbin S. 2001 The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat.276 28179 84 - 39.
Coley W. Van Duyne R. Carpio L. Guendel I. Kehn-Hall K. Chevalier S. Narayanan A. Luu T. Lee N. Klase Z. Kashanchi F. 2011 Absence of DICER in monocytes and its regulation by HIV-1.285 31930 43 - 40.
Cullen B. R. 2000 Nuclear RNA export pathways.20 4181 4187 - 41.
Cullen B. R. 2003 Nuclear mRNA export: insights from virology.28 419 24 - 42.
Damgaard C. K. Kahns S. Lykke-Andersen S. Nielsen A. L. Jensen T. H. Kjems J. 2008 A 5’ splice site enhances the recruitment of basal transcription initiation factors in vivo.29 271 8 - 43.
de la Mata M. Alonso C. R. Kadener S. Fededa J. P. Blaustein M. Pelisch F. Cramer P. Bentley D. Kornblihtt A. R. 2003 A slow RNA polymerase II affects alternative splicing in vivo.12 525 32 - 44.
Deng L. Wang D. de la Fuente C. Wang L. Li H. Lee C. G. Donnelly R. Wade J. D. Lambert P. Kashanchi F. 2001 Enhancement of the300 HAT activity by HIV-1 Tat on chromatin DNA. 289, 312-26 - 45.
Dorr A. Kiermer V. Pedal A. Rackwitz H. R. Henklein P. Schubert U. Zhou M. M. Verdin E. Ott M. 2002 Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain.21 2715 23 - 46.
Dowling D. Nasr-Esfahani S. Tan C. H. O’Brien K. Howard J. L. Jans D. A. Purcell D. F. Stoltzfus C. M. Sonza S. 2008 HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. 5,18 EOF Retrovirology EOF - 47.
Ensoli B. Barillari G. Salahuddin S. Z. Gallo R. C. Wong-Staal F. 1990 Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients.345 84 6 - 48.
Exline C. M. Feng Z. Stoltzfus C. M. 2008 Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression.82 3921 31 - 49.
Fang J. Kubota S. Yang B. Zhou N. Zhang H. Godbout R. Pomerantz R. J. 2004 A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev.330 471 80 - 50.
Fogel B. L. Mc Nally M. T. 2000 A cellular protein, hnRNP H, binds to the negative regulator of splicing element from Rous sarcoma virus.275 32371 32378 - 51.
Fong N. Bentley D. L. 2001 Capping, splicing, and 3’ processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD.15 1783 95 - 52.
Fong Y. W. Zhou Q. 2001 Stimulatory effect of splicing factors on transcriptional elongation.414 929 33 - 53.
Fritz C. C. Zapp M. L. Green M. R. 1995 A human nucleoporin-like protein that specifically interacts with HIV Rev.376 530 3 - 54.
Fujinaga K. Irwin D. Huang Y. Taube R. Kurosu T. Peterlin B. M. 2004 Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element.24 787 95 - 55.
Fukuhara T. Hosoya T. Shimizu S. Sumi K. Oshiro T. Yoshinaka Y. Suzuki M. Yamamoto N. Herzenberg L. A. Hagiwara M. 2006 Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.103 11329 33 - 56.
Garber M. E. Wei P. Kewal Ramani. V. N. Mayall T. P. Herrmann C. H. Rice A. P. Littman D. R. Jones K. A. 1998 The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.12 3512 27 - 57.
Gaynor R. B. 1995 Regulation of HIV-1 gene expression by the transactivator protein tat.193 51 77 - 58.
Giacca M. 2004 The HIV-1 Tat protein: a multifaceted target for novel therapeutic opportunities.4 277 85 - 59.
Gibellini D. Re M. C. La Placa M. Zauli G. 2002 Differentially expressed genes in HIV-1 tat-expressing CD4(+) T-cell line.90 337 45 - 60.
Gilmartin G. M. Fleming E. S. Oetjen J. Graveley B. R. 1995 CPSF recognition of an HIV-1 mRNA 3’-processing enhancer: multiple sequence contacts involved in poly(A) site definition.9 72 83 - 61.
Goldstrohm A. C. Albrecht T. R. Sune C. Bedford M. T. Garcia-Blanco M. A. 2001 The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1.21 7617 28 - 62.
Graveley B. R. 2000 Sorting out the complexity of SR protein functions.6 1197 211 - 63.
Han K. Yeo G. An P. Burge C. B. Grabowski P. J. 2005 A combinatorial code for splicing silencing: UAGG and GGGG motifs. 3,e158 EOF - 64.
Hengartner C. J. Myer V. E. Liao S. M. Wilson C. J. Koh S. S. Young R. A. 1998 Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases.2 43 53 - 65.
Hirose Y. Ohkuma Y. 2007 Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression.141 601 8 - 66.
Hirose Y. Tacke R. Manley J. L. 1999 Phosphorylated RNA polymerase II stimulates pre-mRNA splicing.13 1234 9 - 67.
Ho C. K. Shuman S. 1999 Distinct roles for CTD Ser-2 and Ser-5 phosphorylation in the recruitment and allosteric activation of mammalian mRNA capping enzyme.3 405 11 - 68.
Huang L. Bosch I. Hofmann W. Sodroski J. Pardee A. B. 1998 Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains.72 8952 60 - 69.
Huang Y. Steitz J. A. 2005 SRprises along a messenger’s journey.17 613 5 - 70.
Huigen M. C. Kamp W. Nottet H. S. 2004 Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection.34 57 66 - 71.
Invernizzi C. F. Xie B. Richard S. Wainberg M. A. 2006 PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. 3,93 EOF Retrovirology EOF - 72.
Ivanov D. Kwak Y. T. Guo J. Gaynor R. B. 2000 Domains in the SPT5 protein that modulate its transcriptional regulatory properties.20 2970 83 - 73.
Jablonski J. A. Amelio A. L. Giacca M. Caputi M. 2010 The transcriptional transactivator Tat selectively regulates viral splicing.38 1249 60 - 74.
Jablonski J. A. Buratti E. Stuani C. Caputi M. 2008 The secondary structure of the human immunodeficiency virus type 1 transcript modulates viral splicing and infectivity.82 8038 50 - 75.
Jablonski J. A. Caputi M. 2009 Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity.83 981 92 - 76.
Jacquenet S. Decimo D. Muriaux D. Darlix J. L. 2005 Dual effect of the SR proteins ASF/SF2, SC35 and 9G8 on HIV-1 RNA splicing and virion production. 2,33 EOF Retrovirology EOF - 77.
Kameoka S. Duque P. Konarska M. M. 2004 54 nrb) associates with the 5’ splice site within large transcription/splicing complexes. 23, 1782-91 - 78.
Kamine J. Elangovan B. Subramanian T. Coleman D. Chinnadurai G. 1996 Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator.216 357 66 - 79.
Kaul D. Ahlawat A. Gupta S. D. 2009 HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection.323 143 8 - 80.
Kiernan R. E. Vanhulle C. Schiltz L. Adam E. Xiao H. Maudoux F. Calomme C. Burny A. Nakatani Y. Jeang K. T. Benkirane M. Van Lint C. 1999 HIV-1 tat transcriptional activity is regulated by acetylation.18 6106 18 - 81.
Kim J. B. Sharp P. A. 2001 Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase.276 12317 23 - 82.
King J. E. Eugenin E. A. Buckner C. M. Berman J. W. 2006 HIV tat and neurotoxicity.8 1347 57 - 83.
Klase Z. Kale P. Winograd R. Gupta M. V. Heydarian M. Berro R. Mc Caffrey T. Kashanchi F. 2007 HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. 8,63 EOF - 84.
Klase Z. Winograd R. Davis J. Carpio L. Hildreth R. Heydarian M. Fu S. Mc Caffrey T. Meiri E. Ayash-Rashkovsky M. Gilad S. Bentwich Z. Kashanchi F. 2009 HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. 6,18 EOF Retrovirology EOF - 85.
Komarnitsky P. Cho E. J. Buratowski S. 2000 Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription.14 2452 60 - 86.
Kornblihtt A. R. 2005 Promoter usage and alternative splicing.17 262 8 - 87.
Kornblihtt A. R. 2007 Coupling transcription and alternative splicing.623 175 89 - 88.
Krecic A. M. Swanson M. S. 1999 hnRNP complexes: composition, structure, and function.11 363 71 - 89.
Kwek K. Y. Murphy S. Furger A. Thomas B. O’Gorman W. Kimura H. Proudfoot N. J. Akoulitchev A. 2002 U1 snRNA associates with TFIIH and regulates transcriptional initiation.9 800 5 - 90.
Lamers S. L. Salemi M. Galligan D. C. de Oliveira T. Fogel G. B. Granier S. C. Zhao L. Brown J. N. Morris A. Masliah E. Mc Grath M. S. 2009 Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. 4,e5065 EOF - 91.
Li A. G. Piluso L. G. Cai X. Gadd B. J. Ladurner A. G. Liu X. 2007 An acetylation switch in53 mediates holo-TFIID recruitment. 28, 408-21 - 92.
Lin S. Coutinho-Mansfield G. Wang D. Pandit S. Fu X. D. 2008 The splicing factor SC35 has an active role in transcriptional elongation.15 819 26 - 93.
Mahmoudi T. Parra M. Vries R. G. Kauder S. E. Verrijzer C. P. Ott M. Verdin E. 2006 The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter.281 19960 8 - 94.
Maldarelli F. Martin M. A. Strebel K. 1991 Identification of postranscriptionally active inhibitory sequences in human immunodeficiency virus type I RNA: novel level of gene regulation.65 5732 5743 - 95.
Marcello A. Zoppe M. Giacca M. 2001 Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.51 175 81 - 96.
Marzio G. Tyagi M. Gutierrez M. I. Giacca M. 1998 HIV-1 tat transactivator recruits300 and CREB-binding protein histone acetyltransferases to the viral promoter. 95, 13519-24 - 97.
Mc Laren M. Asai K. Cochrane A. 2004 A novel function for Sam68: enhancement of HIV-1 RNA 3’ end processing.10 1119 29 - 98.
Mc Laren M. Marsh K. Cochrane A. 2008 Modulating HIV-1 RNA processing and utilization.13 5693 707 - 99.
Mikaelian I. Krieg M. Gait M. J. Karn J. 1996 Interaction of INS (CRS) elements and the splicing machinery regulate the production of Rev-responsive mRNAs.257 246 264 - 100.
Min H. Chan R. C. Black D. L. 1995 The generally expressed hnRNP F is involved in a neural-specific pre-mRNA splicing event.9 2659 2671 - 101.
Misteli T. Spector D. L. 1999 RNA polymerase II targets pre-mRNA splicing factors to transcription sites in vivo.3 697 705 - 102.
Moore M. J. Query C. C. Sharp P. A. 1993 Splicing of precursors to mRNA by the spliceosome. In The RNA World, ed. R. F. Gesteland and J. F. Atkins,303 357 New York: Cold Spring Harbor Press - 103.
Mouland A. J. Coady M. Yao X. J. Cohen E. A. 2002 Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression.292 321 30 - 104.
Nasioulas G. Zolotukhin A. S. Tabernero C. Solomin L. Cunningham C. P. Pavlakis G. N. Felber B. K. 1994 Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA.68 2986 93 - 105.
Neff C. P. Zhou J. Remling L. Kuruvilla J. Zhang J. Li H. Smith D. D. Swiderski P. Rossi J. J. Akkina R. 2011 An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. 3,66ra6 EOF - 106.
Ni Z. Schwartz B. E. Werner J. Suarez J. R. Lis J. T. 2004 Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes.13 55 65 - 107.
Olsen H. S. Cochrane A. W. Rosen C. 1992 Interaction of cellular factors with intragenic cis-acting repressive sequences within the HIV genome.191 709 15 - 108.
Orphanides G. Reinberg D. 2002 A unified theory of gene expression.108 439 51 - 109.
Ott M. Lovett J. L. Mueller L. Verdin E. 1998 Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors.160 2872 80 - 110.
Ouellet D. L. Plante I. Landry P. Barat C. Janelle M. E. Flamand L. Tremblay M. J. Provost P. 2008 Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element.36 2353 65 - 111.
Parada C. A. Roeder R. G. 1999 A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription.18 3688 701 - 112.
Pereira L. A. Bentley K. Peeters A. Churchill M. J. Deacon N. J. 2000 A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter.28 663 8 - 113.
Peretti S. Schiavoni I. Pugliese K. Federico M. 2006 Selective elimination of HIV-1-infected cells by Env-directed, HIV-1-based virus-like particles.345 115 26 - 114.
Perron M. P. Provost P. 2008 Protein interactions and complexes in human microRNA biogenesis and function.13 2537 47 - 115.
Peterlin B. M. Price D. H. 2006 Controlling the elongation phase of transcription with P-TEFb.23 297 305 - 116.
Pollard V. W. Malim M. H. 1998 The HIV-1 rev protein.52 491 532 - 117.
Proudfoot N. J. Furger A. Dye M. J. 2002 Integrating mRNA processing with transcription.108 501 12 - 118.
Purcell D. F. J. Martin M. A. 1993 Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication and infectivity.67 6365 6378 - 119.
Purzycka K. J. Adamiak R. W. 2008 The HIV-2 TAR RNA domain as a potential source of viral-encoded miRNA. A reconnaissance study.511 2 - 120.
Raha T. Cheng S. W. Green M. R. 2005 HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. 3,e44 EOF - 121.
Reddy T. R. Tang H. Xu W. Wong-Staal F. 2000 Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA.19 3570 5 - 122.
Reddy T. R. Xu W. Mau J. K. Goodwin C. D. Suhasini M. Tang H. Frimpong K. Rose D. W. Wong-Staal F. 1999 Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev.5 635 42 - 123.
Rodriguez M. S. Dargemont C. Stutz F. 2004 Nuclear export of RNA.96 639 55 - 124.
Rubartelli A. Poggi A. Sitia R. Zocchi M. R. 1998 HIV-I Tat: a polypeptide for all seasons.19 543 5 - 125.
Ruhl M. Himmelspach M. Bahr G. M. Hammerschmid F. Jaksche H. Wolff B. Aschauer H. Farrington G. K. Probst H. Bevec D. et al. 1993 Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation.123 1309 20 - 126.
Sanchez-Alvarez M. Goldstrohm A. C. Garcia-Blanco M. A. Sune C. 2006 Human transcription elongation factor CA150 localizes to splicing factor-rich nuclear speckles and assembles transcription and splicing components into complexes through its amino and carboxyl regions.26 4998 5014 - 127.
Schaub M. C. Lopez S. R. Caputi M. 2007 Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes.282 13617 26 - 128.
Secchiero P. Zella D. Capitani S. Gallo R. C. Zauli G. 1999 Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells.162 2427 31 - 129.
Shatkin A. J. Manley J. L. 2000 The ends of the affair: capping and polyadenylation.7 838 42 - 130.
Smith M. J. Kulkarni S. Pawson T. 2004 FF domains of CA150 bind transcription and splicing factors through multiple weak interactions.24 9274 85 - 131.
Stoltzfus C. M. Madsen J. M. 2006 Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing.4 43 55 - 132.
Suhasini M. Reddy T. R. 2009 Cellular proteins and HIV-1 Rev function.7 91 100 - 133.
Sune C. Garcia-Blanco M. A. 1999 Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.19 4719 28 - 134.
Treand C. du Chene. I. Bres V. Kiernan R. Benarous R. Benkirane M. Emiliani S. 2006 Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter.25 1690 9 - 135.
Urcuqui-Inchima S. Castano M. E. Hernandez-Verdun D. St-Laurent G. 3rd Kumar A. 2006 Nuclear Factor 90, a cellular dsRNA binding protein inhibits the HIV Rev-export function. 3,83 EOF Retrovirology EOF - 136.
Valente S. T. Goff S. P. 2006 Inhibition of HIV-1 gene expression by a fragment of hnRNP U.23 597 605 - 137.
Van Lint C. Quivy V. Demonte D. Chariot A. Vanhulle C. de Walque S. Gaudray G. Veithen E. Bours V. Piette J. Burny A. 2004 Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies.159 176 89 - 138.
Verdel A. Jia S. Gerber S. Sugiyama T. Gygi S. Grewal S. I. Moazed D. 2004 RNAi-mediated targeting of heterochromatin by the RITS complex.303 672 6 - 139.
Verdin E. Paras P. Jr Van Lint C. 1993 Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.12 3249 59 - 140.
Wada T. Orphanides G. Hasegawa J. Kim D. K. Shima D. Yamaguchi Y. Fukuda A. Hisatake K. Oh S. Reinberg D. Handa H. 2000 FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH.5 1067 72 - 141.
Wada T. Takagi T. Yamaguchi Y. Ferdous A. Imai T. Hirose S. Sugimoto S. Yano K. Hartzog G. A. Winston F. Buratowski S. Handa H. 1998a DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs.12 343 56 - 142.
Wada T. Takagi T. Yamaguchi Y. Watanabe D. Handa H. 1998b Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro.17 7395 403 - 143.
Wei P. Garber M. E. Fang S. M. Fischer W. H. Jones K. A. 1998 A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.92 451 62 - 144.
Weichs an. der Glon C. Monks J. Proudfoot N. J. 1991 Occlusion of the HIV poly(A) site.5 244 53 - 145.
Weissman J. D. Brown J. A. Howcroft T. K. Hwang J. Chawla A. Roche P. A. Schiltz L. Nakatani Y. Singer D. S. 1998 HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes.95 11601 6 - 146.
Wen Y. Shatkin A. J. 1999 Transcription elongation factor hSPT5 stimulates mRNA capping.13 1774 9 - 147.
Wentz P. M. Moore B. E. Cloyd M. V. Berget S. M. Donehower L. A. 1997 A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type I induces dominant aberrant splicing and arrests virus production.71 8542 8551 - 148.
Winter J. Jung S. Keller S. Gregory R. I. Diederichs S. 2009 Many roads to maturity: microRNA biogenesis pathways and their regulation 11 228 34 - 149.
Wodrich H. Krausslich H. G. 2001 Nucleocytoplasmic RNA transport in retroviral replication.34 197 217 - 150.
Woychik N. A. Hampsey M. 2002 The RNA polymerase II machinery: structure illuminates function.108 453 63 - 151.
Wu R. F. Ma Z. Myers D. P. Terada L. S. 2007 HIV-1 Tat activates dual Nox pathways leading to independent activation of ERK and JNK MAP kinases.282 37412 9 - 152.
Yamaguchi Y. Takagi T. Wada T. Yano K. Furuya A. Sugimoto S. Hasegawa J. Handa H. 1999 NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation.97 41 51 - 153.
Yamamoto T. Omoto S. Mizuguchi M. Mizukami H. Okuyama H. Okada N. Saksena N. K. Brisibe E. A. Otake K. Fuji Y. R. 2002 Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication.46 809 17 - 154.
Yang X. J. Seto E. 2008 Lysine acetylation: codified crosstalk with other posttranslational modifications.31 449 61 - 155.
Yedavalli V. S. Neuveut C. Chi Y. H. Kleiman L. Jeang K. T. 2004 Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function.119 381 92 - 156.
Zahler A. M. Damgaard C. K. Kjems J. Caputi M. 2004 SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing.279 10077 84 - 157.
Zhou M. Deng L. Kashanchi F. Brady J. N. Shatkin A. J. Kumar A. 2003 The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA.100 12666 71 - 158.
Zhou M. Halanski M. A. Radonovich M. F. Kashanchi F. Peng J. Price D. H. Brady J. N. 2000 Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.20 5077 86 - 159.
Zhou Q. Sharp P. A. 1996 Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat.274 605 10